title: Current Status and Perspectives Regarding LNA-Anti-miR Oligonucleotides and microRNA miR-21 Inhibitors as a Potential Therapeutic Option in Treatment of Colorectal Cancer.
abstract: Colorectal cancer (CRC) is among the leading causes of cancer-related death, principally due to its metastatic spread and multifactorial chemoresistance. The therapeutic failure can also be explained by inter- or intra-tumor genetic heterogeneity and tumor stromal content. Thus, the identification of novel prognostic biomarkers and therapeutic options are warranted in the management of CRC patients. There are data showing that microRNA-21 is elevated in different types of cancer, particularly colon adenocarcinoma and that this is association with a poor prognosis. This suggests that microRNA-21 may be of value as a potential therapeutic target. Furthermore, locked nucleic acid (LNA)-modified oligonucleotides have recently emerged as a therapeutic option for targeting dysregulated miRNAs in cancer therapy, through antisense-based gene silencing. Further work is required to identify innovative anticancer drugs that improve the current therapy either through novel combinatorial approaches or with better efficacy than conventional drugs. We aimed to provide an overview of the preclinical and clinical studies targeting key dysregulated signaling pathways in CRC as well as the therapeutic application of LNA-modified oligonucleotides, and miR inhibitors in the treatment of CRC patients. J. Cell. Biochem. 118: 4129-4140, 2017. © 2017 Wiley Periodicals, Inc.
authors.affiliation: Deputy of Food and Drug, Isfahan University of Medical Sciences, Isfahan, Iran.|Student Research Committee, Department of medical biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Reza
authors.initials: R
authors.lastname: Nedaeinia
authors.affiliation: Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.|Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Amir
authors.initials: A
authors.lastname: Avan
authors.affiliation: Department of Gastroentrology, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Mehdi
authors.initials: M
authors.lastname: Ahmadian
authors.affiliation: Department of Agricultural engineering and Weed science, Shiraz Branch, Islamic Azad University, Shiraz, Iran.
authors.forename: Sasan Nedaee
authors.initials: SN
authors.lastname: Nia
authors.affiliation: Deputy of Food and Drug, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Maryam
authors.initials: M
authors.lastname: Ranjbar
authors.affiliation: Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Mohammadreza
authors.initials: M
authors.lastname: Sharifi
authors.affiliation: Department of Food Science and Technology, Isfahan (Khorasgan) Branch, Islamic Azad University, Isfahan, Iran.
authors.forename: Mohammad
authors.initials: M
authors.lastname: Goli
authors.affiliation: School of Medicine, Kashan University of Medical Sciences, Autoimmune Diseases Research Center, Kashan, Iran.
authors.forename: Ahmad
authors.initials: A
authors.lastname: Piroozmand
authors.affiliation: Student Research Committee, Department of medical biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Esmail
authors.initials: E
authors.lastname: Nourmohammadi
authors.affiliation: Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
authors.forename: Mostafa
authors.initials: M
authors.lastname: Manian
authors.affiliation: Brighton and Sussex Medical School, Division of Medical Education, Falmer, Brighton BN1 9PH, Sussex, UK.
authors.forename: Gordon A
authors.initials: GA
authors.lastname: Ferns
authors.affiliation: Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.|Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Majid
authors.initials: M
authors.lastname: Ghayour-Mobarhan
authors.affiliation: Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Rasoul
authors.identifier: 0000-0003-4062-6166
authors.initials: R
authors.lastname: Salehi
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D035683:MicroRNAs / Q000037:antagonists & inhibitors*; D009841:Oligonucleotides / Q000494:pharmacology*; D015398:Signal Transduction
chemical_list: D000970:Antineoplastic Agents; C524940:MIRN21 microRNA, human; D035683:MicroRNAs; D009841:Oligonucleotides; C477371:locked nucleic acid
keywords: COLORECTAL CANCER; GENE THERAPY; LNA; MicroRNAs; miR-21